Drug Trial Radar · NCT07205718
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
273
Planned (sponsor's estimate)
Start
Nov 19, 2025
Primary completion
Dec 26, 2028
Study completion Dec 21, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
TAK-188Drug
TAK-188 IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: From the signing of the informed consent form (ICF) through 90 days after the last dose (Up to approximately 16 months)
- Phase 1: Number of Participants with TEAEs Based on SeverityTime frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)
- Phase 1: Number of Participants with Dose- limiting Toxicities (DLTs)Time frame: Up to Cycle 1 (21 days)
- Phase 1: Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)Time frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)
- Phase 1: Number of Participants with Treatment-emergent Adverse Events Leading to Dose Modifications and Treatment DiscontinuationsTime frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)
- Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to 24 months
- Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Disease Control Rate (DCR)Time frame: Up to 24 months
- Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Duration of Response (DOR)Time frame: Up to 24 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica)
Santa Monica, California · Recruiting
Yale School of Medicine - Smilow Cancer Hospital - Center for Thoracic Cancers
New Haven, Connecticut · Recruiting
Florida Cancer Specialists - Lake Nona
Orlando, Florida · Recruiting
Johns Hopkins
Baltimore, Maryland · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Providence Cancer Institute, Franz Clinic
Portland, Oregon · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
SCRI Oncology
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.